Quantitative detection of ANTI-PROTEIN S antibodies of SARS-CoV-2 in vaccinated personnel of Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine), city of Córdoba, Argentina
Abstract Vaccination against SARS-CoV-2 began in Argentina in December 2020. We measured the concentration of antibodies generated by the different vaccines and doses with the aim of evaluating the humoral immune response to them. Materials and methods: Descriptive, cross-sectional and retrospective...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2021
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/34914 |
| Aporte de: |
| Sumario: | Abstract
Vaccination against SARS-CoV-2 began in Argentina in December 2020. We measured the concentration of antibodies generated by the different vaccines and doses with the aim of evaluating the humoral immune response to them.
Materials and methods: Descriptive, cross-sectional and retrospective study. IgG anti-protein S antibodies of SARS-CoV-2 (ABBOTT) were quantitatively determined in sera from 41 staff members at Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine). The study was approved by the Comité de Investigación y Docencia institucional (Institutional Research and Teaching Committee). The inclusion criteria covered vaccinated personnel. Results: the mean age was 40 ± 9 years (25 to 62). 33 participants were female, and 33 participants did not have the infection. 33 received both doses. We evaluated 1 to 9 blood samples per participant from January to June 2021. Average: 3± 2 samples. Total: 134 samples. 23 participants were vaccinated with Sputnik V, 12 with Oxford-AstraZeneka-Covishield and 6 with Sinopharm. Participants with or without infection and with one or both doses were grouped together. With previous infection, the post-first dose value was 20800.27 ± 14004 (4267.5 to 36057.3). The average follow-up time was 31 days after administration. For the second dose, the follow-up time was 61 days; and the average antibody concentration was 11175.65 ± 10248.74 (2019.9 to 32618.5). There were no differences between doses (p: 0.7220). There was a difference when compared with those who did not have the infection (p<0.0001). No significant differences were observed between vaccines, regardless of what dose was administered (1st dose, p: 0.6824; 2nd dose, p: 0.5549). In uninfected: Oxford-AstraZeneca-Covishield 1 average dose 504.8 ± 1097.9, and with 2 doses 2223.48 ± 2906.8 (p<0.0001), Sinopharm 62.2 ± 59.4 and 937.7 ± 467.2 respectively (p<0.0001), Sputnik V, 213.2 ± 352.4 and 1893.3 ± 2347.7 (p<0.0001). All participants generated antibodies after being vaccinated.
Conclusions-Relevance of the work: The three vaccines evaluated generated a statistically similar anti-S antibody immune response with high effectiveness. Those who get the infection before or after getting vaccinated reach statistically higher levels of antibodies. The second doses generate statistically higher levels of antibodies in uninfected participants. |
|---|